


PHARMACEUTICAL 2017



INTEGRATED BIOPHARMA INC Rank 229 of 292





PHARMACEUTICAL 2017



INTEGRATED BIOPHARMA INC Rank 229 of 292

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 183% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 169% points.

The company's Economic Capital Ratio, given in the ranking table, is -73%, being 76% points below the market average of 2.9%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 12,070 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 235 |
| Liabilities, Current | 11,824 |
| Liabilities, Non-Current | 5,306 |
| Other Assets | 213 |
| Other Compr. Net Income | 0 |
| Other Expenses | 36,941 |
| Other Liabilities | 5,282 |
| Other Net Income | -925 |
| Other Revenues | 42,214 |
| Property and Equipment | 1,567 |
| Research and Development | 0 |
| Selling, General and Administrative Expense | 3,390 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 14,085 |
| Liabilities | 22,412 |
| Expenses | 40,331 |
| Revenues | 42,214 |
| Stockholders Equity | -8,327 |
| Net Income | 958 |
| Comprehensive Net Income | 958 |
| Economic Capital Ratio | -73% |

